Immunotherapy for Infectious Diseases

Viral Infections Other than HIV 257
8. Johnson S, Griego SD, Pfarr DS, et al. A direct comparison of two humanized respiratory
syncytial virus monoclonal antibodies: MEDI-493 and RSHZ19. J Infect Dis 1999;
180:35–40.
9. The Impact RSV Study Group. Palivizumab, a humanized respiratory syncytial virus monoclonal
antibody, reduces hospitalization from respiratory syncytial virus infection in highrisk
infants. Pediatrics 1998; 102:531–537.
10. American Academy of Pediatrics—Committee on Infectious Diseases and Committee on
Fetus and Newborn. Prevention of respiratory syncytial virus infections: indications for the
use of palivizumab and update on the use of RSV-IVIG. Pediatrics 1998; 102:1211–1216.
11. Randwaha PS, Yousem SA, Paradis IL, et al. The clinical spectrum, pathology, and clonal
analysis of Epstein-Barr virus associated lymphoproliferative disorders in heart-lung transplant
reciepients. Am J Clin Pathol. 1989; 92:177.
12. Shapiro RS, McClain K, Frizzera G, et al. Epstein-Barr virus associated B-cell lymphoproliferative
disorders following bone marrow transplantation. Blood 1988; 71:1234–1243.
13. Seeley J, Svedmyr OLA, Weiland GK, et al. Epstein-Barr virus selective T cells in infectious
mononucleosis are not restricted to HLA-A and B antigens. J Immunol 1981;
127:293–300.
14. Masucci MG, Bejarano MT, Masucci G, et al. Large granular lymphocytes inhibit the in
vitro growth of autologous Epstein-Barr virus-infected cells. Cell Immunol 1981;
127:293–300.
15. Rickinson AB, Moss DJ, Wallace LE, et al. Long-term T cell-mediated immunity to Epstein
Barr virus. Cancer Res 1981; 41:4216–4221.
16. O’Reilly RJ, Small TN, Papdopoulos E, Lucas K, Lacerda J, Koulova L. Adoptive
immunotherapy for Epstein-Barr virus-associated lymphoproliferative disorders complicating
marrow allografts. Springer Semin Immunopathol 1998; 20:455–491.
17. Rooney CM, Smith C, Ng CY, et al. Infusion of cytotoxic T cells for the prevention and
treatment of Epstein-Barr virus-induced lymphoma in allogenic transplant recipients. Blood
1998; 5:1549–1555.
18. Small TN, Avigan D, Dupont B, et al. Immune reconstitution following T cell depleted bone
marrow transplantation; effect of age and post-transplant graft rejection prophylaxis. Biol
Blood Marrow Transplant 1997; 2:65.
19. Emanuel DJ, Lucas KG, Mallory GB, et al. Treatment of post-transplant lymphoproliferative
disease in the central nervous system of a lung transplant recipient using allogenic
leukocytes. Transplantation 1997; 63:1691.
20. Nalesnik MA, Rao AS, Furukawa H, et al. Autologous lymphokine-activated killer cell
therapy of Epstein-Barr virus-positive and -negative lymphoproliferative disorders arising
in organ transplant recipients. Transplantation 1997; 63:1200.
21. McGuirk JP, Seropian S, Howe G, Smith B, Stoddard L, Cooper DL. Use of rituximab and
irradiated donor-derived lymphocytes to control Epstein-Barr virus-associated lymphoproliferation
in patients undergoing related haplo-identical stem cell transplantation. Bone
Marrow Transplant 1999; 24:1253–1258.
22. Cook RC, Connors JM, Gascoyne RD, Fradet G, Levy RD. Treatment of post-transplant
lymphoproliferative disease with rituximab monoclonal antibody after lung transplantation.
Lancet 1999; 354:1698–1699.
23. Rossol S, Marinos G, Caruscci P, Singer MV, Williams R, Naoumonv NV. Interleukin-12
induction of Th1 cytokines is important for viral clearance in chronic hepatitis B. J Clin
Invest 1997; 99:3025–3033.
24. Gilles PN, Fey G, Chisari FV. Tumor necrosis factor negatively regulates hepatitis B virus
gene expression in transgenic mice. J Virol 1992; 66:3955–3960.
25. Guilhot S, Guidotti LG, Chisari FV. Interleukin 2 and interferon alpha/beta downregulate
hepatitis B virus gene expression in transgenic mice by a posttranscriptional mechanism.
J Virol 1993; 67:7444–7449.